Entorhinal Cortex Layer II Neurons in Alzheimer's Disease

Entorhinal Cortex Layer II Neurons in Alzheimer's Disease

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Entorhinal Cortex Layer II Neurons in Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Gene/Protein</td>
<td>Role in EC Layer II</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>Cholesterol transport, synaptic maintenance</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Microtubule stabilization, axonal transport</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Amyloid precursor protein, synaptic function</td>
</tr>
<tr>
<td class="label">PSEN1</td>
<td>γ-secretase component, Aβ generation</td>
</tr>
<tr>
<td class="label">PSEN2</td>
<td>γ-secretase component, Aβ generation</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Microglial phagocytosis receptor</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Neuronal survival, synaptic plasticity</td>
</tr>
<tr>
<td class="label">CREB1</td>
<td>Transcription factor, memory consolidation</td>
</tr>
</table>

Entorhinal Cortex Layer Ii Neurons In Alzheimer'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.

Overview

Entorhinal Cortex Layer II Neurons in Alzheimer's Disease

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Entorhinal Cortex Layer II Neurons in Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Gene/Protein</td>
<td>Role in EC Layer II</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>Cholesterol transport, synaptic maintenance</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Microtubule stabilization, axonal transport</td>
</tr>
<tr>
<td class="label">APP</td>
<td>Amyloid precursor protein, synaptic function</td>
</tr>
<tr>
<td class="label">PSEN1</td>
<td>γ-secretase component, Aβ generation</td>
</tr>
<tr>
<td class="label">PSEN2</td>
<td>γ-secretase component, Aβ generation</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>Microglial phagocytosis receptor</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Neuronal survival, synaptic plasticity</td>
</tr>
<tr>
<td class="label">CREB1</td>
<td>Transcription factor, memory consolidation</td>
</tr>
</table>

Entorhinal Cortex Layer Ii Neurons In Alzheimer'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.

Overview

Entorhinal cortex layer II neurons are among the first neurons to die in Alzheimer's disease. These neurons project to the dentate gyrus via the perforant path and are critical for memory and spatial navigation. Their early vulnerability makes them a key focus for understanding AD pathogenesis. [@braak1991]

Location and Structure

The entorhinal cortex is located in the medial temporal lobe, forming the gateway to the hippocampus: [@khan2014]

• Layer II: Islands of large neurons (stellate cells)
• Layer III: Smaller pyramidal neurons
• Layer V: Large pyramidal neurons
• Medial entorhinal cortex: Grid cell inputs
• Lateral entorhinal cortex: Object/odor information

Normal Function

Perforant Path

• Layer II neurons project to dentate gyrus
• Major input to hippocampal formation
• Conveys cortical information to hippocampus
• Critical for memory encoding

Grid Cell Inputs

• Medial entorhinal grid cells
• Provide spatial navigation signals
• Support path integration
• Coordinate with place cells

Memory Processing

• Initial processing for episodic memory
• Bind cortical sensory information
• Temporal ordering of events
• Support spatial memory

Vulnerability in Alzheimer's Disease

Earliest Degeneration

• First neurons affected in AD
• Neurofibrillary tangles appear early (Braak stage I-II)
• Severe neuron loss before clinical symptoms
• Braak staging correlates with cognitive decline

Why These Neurons Are Vulnerable

• High metabolic demand
• Long axonal projections
• Tangle pathology spreads through connectivity
• tau pathology originates here

Pathology

• Neurofibrillary tangles: Hyperphosphorylated tau
• Neuron loss in layer II
• Reduced synaptic density
• Impaired connectivity to hippocampus

Molecular Mechanisms

tau Pathology

• Hyperphosphorylated tau in cell bodies
• Spreads transneuronally
• Related to microtubule dysfunction
• Impairs axonal transport

Amyloid Interactions

• Aβ affects layer II neurons
• Synaptic dysfunction
• Disrupted neural circuits
• May accelerate tau pathology

Other Factors

• Oxidative stress
• [Neuroinflammation](/mechanisms/neuroinflammation) Impaired glucose metabolism
• Mitochondrial dysfunction

Key Genes and Proteins

Signaling Pathways

tau Phosphorylation Cascade

Amyloid-tau Interaction

Neuroinflammation Signaling

```

Disease Associations

Alzheimer's Disease Staging

• Braak Stage I-II: NFT pathology begins in EC layer II
• Preclinical AD: Subtle changes before cognitive symptoms
• MCI: Significant EC atrophy detectable on MRI
• Moderate AD: Severe layer II neuron loss

Regional Vulnerability

• Medial entorhinal cortex (MEC) affected first
• Lateral entorhinal cortex (LEC) follows
• Grid cell dysfunction correlates with spatial memory deficits
• Layer II stellate cells particularly vulnerable

Clinical Correlations

Biomarkers

• MRI: Entorhinal cortex atrophy earliest MRI change
• CSF: Elevated p-tau181 indicates EC pathology
• PET: Tau PET shows early tracer uptake in EC
• FDG-PET: Hypometabolism in EC layer II

Cognitive Symptoms

• Spatial disorientation (grid cell damage)
• Episodic memory deficits (perforant path disruption)
• Navigation impairment (head direction cell involvement)
• Temporal ordering problems (cortical input disruption)

Research Highlights

Key Findings

[@van2009]: Braak H, et al. (2011). Stages of the pathologic process in Alzheimer disease. Acta Neuropathol.
[@braak1991]: Liu L, et al. (2012). Transneuronal propagation of pathologic tau. Neuron.
[@khan2014]: Yao J, et al. (2010). Mitochondrial bioenergetic deficit precedes Alzheimer's pathology. J Neurosci.
[@knopman2019]: Knopman DS, et al. (2019). Alzheimer disease: Natural history and targets for clinical trials. Nat Rev Neurol.

Therapeutic Implications

Early Detection

• Entorhinal atrophy on MRI
• CSF biomarkers (p-tau)
• PET imaging for tau
• Electrophysiological markers

Treatment Strategies

• Anti-tau antibodies
• tau aggregation inhibitors
• Neuroprotective compounds
• Neural circuit restoration

Future Directions

• Early intervention targeting layer II
• tau immunotherapy
• Stem cell-based replacement
• Circuit-specific therapies

Background

The study of Entorhinal Cortex Layer Ii Neurons In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
• [Tau Pathology](/mechanisms/tau-pathology)
• [APP Processing](/mechanisms/app-processing)
• [Amyloid Aggregation](/mechanisms/amyloid-aggregation)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data